Focused issue on “Melanoma”--Guest Edited by Dr. María González-Cao

Posted On 2015-11-03 09:56:18

For decades there were no advances in treatment for metastatic melanoma, although old immunotherapy modalities, such as high doses of IL-2 or cellular vaccines, demonstrated activity in some individual cases, median survival of metastatic melanoma patients did not improve. In recent years this situation has changed dramatically. Several active treatments for melanoma have been approved and now melanoma is a model for the development of treatment for other tumors. Drugs such as BRAF and MEK inhibitors obtain a clear survival advantage with high response rates. Immunotherapy with anti CTLA-4 antibody (ipilimumab) and the anti PD-1/PD-L1 inhibitors (nivolumab and pembrolizumab) has demonstrated activity with long lasting responses.

This focused Issue reviews the state of the art in melanoma. Experts in the field review the most relevant findings about biology, genetics and new treatments for melanoma. We try to provide simple keys of lecture that might help illustrate the conceptual basis and at least some of the potential future developments for melanoma management.


Preface

Focused issue on “Melanoma”
María González-Cao

Review Article

Recent advances in the treatment of melanoma with BRAF and MEK inhibitor
Eva Muñoz-Couselo, Jesús Soberino García, José Manuel Pérez-García, Vanesa Ortega Cebrián, Javier Cortés Castán
Predictive factors for immunotherapy in melanoma
Cristina Teixidó, Maria González-Cao, Niki Karachaliou, Rafael Rosell
Epigenetic mechanisms involved in melanoma pathogenesis and chemoresistance
Anna Martinez-Cardús, Miguel Vizoso, Sebastian Moran, Jose Luis Manzano
Update in genetic susceptibility in melanoma
Miriam Potrony, Celia Badenas, Paula Aguilera, Joan Anton Puig-Butille, Cristina Carrera, Josep Malvehy, Susana Puig

Melanoma: oncogenic drivers and the immune system
Niki Karachaliou, Sara Pilotto, Cristina Teixidó, Santiago Viteri, Maria Gonzalez-Cao, Aldo Riso, Daniela Morales-Espinosa, Miguel Angel Molina, Imane Chaib, Mariacarmela Santarpia, Eduardo Richardet, Emilio Bria, Rafael Rosell
Other targeted drugs in melanoma
María González-Cao, Jordi Rodón, Niki Karachaliou, Jesús Sánchez, Mariacarmela Santarpia, Santiago Viteri, Sara Pilotto, Cristina Teixidó, Aldo Riso, Rafael Rosell
Immune checkpoint inhibitors: therapeutic advances in melanoma
Ivan Márquez-Rodas, Pablo Cerezuela, Ainara Soria, Alfonso Berrocal, Aldo Riso, María González-Cao, Salvador Martín-Algarra
cfDNA analysis from blood in melanoma
Miguel A. Molina-Vila, Clara Mayo-de-las-Casas, Jordi Bertran-Alamillo, Nuria Jordana-Ariza, María González-Cao, Rafael Rosell

Resistant mechanisms to BRAF inhibitors in melanoma
José Luís Manzano, Laura Layos, Cristina Bugés, María de los Llanos Gil, Laia Vila, Eva Martínez-Balibrea, Anna Martínez-Cardús

Uveal melanoma as a target for immune-therapy
Marc Oliva, Antonio J. Rullan, Josep M. Piulats

Guest Editor: Maria González Cao, MD Department of Medical Oncology, Instituto Oncológico Dr Rosell (IOR), Hospital Universitario Quirón Dexeus, Barcelona, Spain